Posts by Charlie Schmidt
For men who have had prostate gland removal surgery, results from a new study show that a combination of radiation treatment and androgen deprivation therapy is more effective for treating PSA recurrence than radiation alone.
In a British study, a specialized type of MRI test did significantly better at identifying high-grade prostate tumors than a transrectal ultrasound biopsy. It’s hoped that one day this test might help men avoid prostate biopsies and their potential complications.
After prostate cancer surgery, the patient’s prostate-specific antigen (PSA) is monitored by his doctor via a simple blood test. New research indicates that if the PSA increases following surgery, immediate radiation therapy can reduce the risk of cancer recurrence.
Two new studies add to the evidence that for many men with prostate cancer, if it is detected early and has not metastasized beyond the prostate gland, monitoring the cancer will lead to the same chance of survival after 10 as choosing surgery or radiation. Men treated with surgery or radiation often experience significant side effects. The rates of depression and anxiety were the same in men who opted for monitoring and those who opted for treatment.
For men with prostate cancer that has metastasized, treatment usually focuses on the tumors that develop elsewhere in the body. But treating the primary tumor in the prostate with radiation or surgery could result in longer overall survival.
Researchers believe that a non-invasive screening test that can identify genetic markers for high-grade prostate cancer in urine may eventually reduce the number of prostate biopsies needed. However, experts also caution that while the number of non-invasive tests for prostate cancer diagnosis is growing, these are still early days in their development.
Many men with prostate cancer benefit from active surveillance, in which treatment doesn’t begin unless the cancer spreads. There has been some debate about whether this strategy is safe for men with intermediate-risk prostate cancer. A new study suggests that this type of cancer is more likely to spread than previously thought — but active surveillance can still be a good option for many intermediate-risk men.
Long-term hormonal therapy, which blocks the effect of testosterone on prostate tumors, was once reserved for prostate cancer that has spread. But recent research has found that it had enormous benefits for men with earlier stages of prostate cancer, slashing their risks of metastasis and death from prostate cancer. However, some questions remain — for example, exactly how long to use “long-term hormonal therapy” is still up for debate.
The same BRCA mutations that increase a woman’s risk of breast and ovarian cancers can also increase a man’s risk of dying from prostate cancer. Recently, an ovarian cancer drug intended for BRCA-positive women has shown impressive results in BRCA-positive men with metastatic prostate cancer. This drug, and others like it, could provide another, much-needed treatment option for men with advanced prostate cancer.
Fewer men are being given PSA tests to screen for prostate cancer. As screening rates have fallen, so have the number of prostate cancer diagnoses. This probably also means that fewer men are receiving potentially unnecessary treatment, with its attendant negative side effects. At the same time, it isn’t yet clear whether that comes at the cost of more aggressive cancers being caught at an incurable stage. Better screening tests may make the difference in helping strike the right balance between limiting harm and preventing prostate cancer deaths.